Atara Biotherapeutics, INC. (ATRA) — SEC Filings

Q: What are the key financial highlights for Atara Biotherapeutics, INC.?

Key financial highlights for Atara Biotherapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Atara Biotherapeutics, INC.?

Key executives at Atara Biotherapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Atara Biotherapeutics, INC. stock?

Risk factors for Atara Biotherapeutics, INC. (ATRA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Atara Biotherapeutics, INC.?

Forward-looking statements and predictions from Atara Biotherapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Atara Biotherapeutics, INC.. Recent EFFECT filing on Mar 26, 2026. AI-decoded analysis of earnings, risk factors, and insider trades

View Atara Biotherapeutics, INC. on SEC EDGAR

Overview

Atara Biotherapeutics, INC. (ATRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Mar 26, 2026: The SEC has declared the registration statement for Atara Biotherapeutics, Inc. (CIK: 0001604464) effective as of March 25, 2026. This means the company can now proceed with its planned offering of securities under File No. 333-294377. For investors, this is a procedural step indicating the company

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Atara Biotherapeutics, INC. is neutral.

Filing Type Overview

Atara Biotherapeutics, INC. (ATRA) has filed 1 EFFECT, 6 10-Q, 24 8-K, 2 DEF 14A, 13 SC 13G/A, 1 SC 13D/A, 1 SC 13D, 1 10-K, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

Atara Biotherapeutics' Registration Statement Effective March 25, 2026 — EFFECT · Mar 26, 2026
The SEC has declared the registration statement for Atara Biotherapeutics, Inc. (CIK: 0001604464) effective as of March 25, 2026. This means the company can now
Atara Swings to Profit YTD, But Cash Dwindles Amid Revenue Dip — 10-Q · Nov 12, 2025 Risk: high
Atara Biotherapeutics, Inc. (ATRA) reported a net income of $36.094 million for the nine months ended September 30, 2025, a significant turnaround from a net lo
Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · Oct 7, 2025 Risk: medium
On October 6, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify doll
Atara Biotherapeutics Announces Executive and Director Changes — 8-K · Sep 4, 2025 Risk: medium
Atara Biotherapeutics, Inc. announced on September 2, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure
Atara Narrows Losses to $58.1M Amid R&D Cuts, Cash Dwindles — 10-Q · Aug 11, 2025 Risk: high
Atara Biotherapeutics, Inc. reported a net loss of $58.1 million for the six months ended June 30, 2025, a significant improvement from the $100.2 million net l
Atara Biotherapeutics Files 8-K: Operations & Financial Update — 8-K · Jul 14, 2025 Risk: low
On July 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns results of operations, financial condition, and other events. I
Atara Biotherapeutics Holds Special Stockholder Meeting — 8-K · Jun 11, 2025 Risk: low
On June 10, 2025, Atara Biotherapeutics, Inc. filed an 8-K report indicating that it held a special meeting of stockholders on June 10, 2025. The primary purpos
Atara Biotherapeutics Files 8-K Report — 8-K · May 16, 2025 Risk: low
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
Atara Biotherapeutics Files 8-K on Leadership and Compensation — 8-K · May 15, 2025 Risk: medium
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
Atara Biotherapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
Atara Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities. Key fin
Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · May 12, 2025 Risk: medium
On May 12, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify the exa
Atara Biotherapeutics Files 8-K — 8-K · May 6, 2025 Risk: low
On May 5, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
Atara Biotherapeutics Executive Compensation Details — DEF 14A · Apr 28, 2025 Risk: low
Atara Biotherapeutics, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
Atara Biotherapeutics Enters Material Definitive Agreement — 8-K · Apr 4, 2025 Risk: medium
On March 31, 2025, Atara Biotherapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, i
Atara Biotherapeutics Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Mar 31, 2025 Risk: medium
On March 25, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
Atara Biotherapeutics Files 8-K on Financials — 8-K · Mar 7, 2025 Risk: low
On March 7, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · Mar 3, 2025 Risk: medium
On March 3, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify dollar
Atara Biotherapeutics Files 8-K on Exit Costs — 8-K · Jan 27, 2025 Risk: medium
On January 27, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns cost associated with exit or disposal activities and include
Atara Biotherapeutics Files 8-K — 8-K · Jan 21, 2025 Risk: low
On January 21, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
Atara Biotherapeutics Files 8-K — 8-K · Jan 16, 2025 Risk: low
On January 16, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
Atara Biotherapeutics Changes Fiscal Year End — 8-K · Dec 23, 2024 Risk: low
Atara Biotherapeutics, Inc. filed an 8-K on December 23, 2024, reporting a change in its fiscal year end to December 31st. This filing does not appear to contai
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Atara Biotherapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Atara Biotherapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations.
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
Atara Biotherapeutics Announces Executive and Board Changes — 8-K · Oct 15, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on October 14, 2024, changes in its executive team and board of directors. The filing details the departure of certain off
SC 13G/A Filing — SC 13G/A · Sep 13, 2024
Adiumentum Capital Fund Amends Atara Biotherapeutics Stake — SC 13D/A · Sep 5, 2024 Risk: medium
On September 5, 2024, Adiumentum Capital Fund I LP, formerly Adiumentum Capital Fund LP, filed an amendment (No. 1) to its Schedule 13D regarding Atara Biothera
Atara Biotherapeutics Announces Board and Executive Changes — 8-K · Sep 3, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on September 3, 2024, changes in its board of directors and executive compensation arrangements. The filing details the de
Atara Biotherapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
Atara Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, inclu
Atara Biotherapeutics Files 8-K Report — 8-K · Jul 17, 2024 Risk: low
On July 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates
SC 13G/A Filing — SC 13G/A · Jul 8, 2024
Atara Biotherapeutics Files 8-K: Rights, Bylaws, and Financials Updated — 8-K · Jun 20, 2024 Risk: medium
On June 20, 2024, Atara Biotherapeutics, Inc. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also includ
Atara Biotherapeutics Files 8-K — 8-K · Jun 17, 2024 Risk: low
On June 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
Atara Biotherapeutics Files 8-K for Security Holder Vote — 8-K · Jun 11, 2024 Risk: low
On June 10, 2024, Atara Biotherapeutics, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not c
Adiumentum Capital Fund I LP Files 13D on Atara Biotherapeutics — SC 13D · May 22, 2024 Risk: medium
On May 22, 2024, Adiumentum Capital Fund I LP, along with Gregory A. Ciongoli, filed a Schedule 13D regarding Atara Biotherapeutics, Inc. This filing indicates
Atara Biotherapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk:
Atara Biotherapeutics, Inc. (ATRA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Atara Biotherapeutics, Inc. filed a 10-Q report for the period e
Atara Biotherapeutics Files DEF 14A for Annual Meeting — DEF 14A · Apr 26, 2024 Risk: low
Atara Biotherapeutics, Inc. (ATRA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Atara Biotherapeutics, Inc. filed a DEF 14A form on April 2
Atara Biotherapeutics Names New CEO, Board Changes — 8-K · Mar 29, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on March 26, 2024, changes in its executive and director roles. Dr. Pascal Touchon has been appointed as the new Chief Exe
Atara Biotherapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk:
Atara Biotherapeutics, Inc. (ATRA) filed a Annual Report (10-K) with the SEC on March 28, 2024. Atara Biotherapeutics, Inc. filed its 2023 Form 10-K on March 28
SC 13G Filing — SC 13G · Mar 18, 2024
Atara Biotherapeutics Reports Executive Changes and Compensation Updates — 8-K · Feb 23, 2024 Risk: medium
Atara Biotherapeutics, Inc. filed an 8-K on February 22, 2024, reporting on the departure of directors or certain officers, election of directors, appointment o
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Wasatch Advisors LP Divests Entire Stake in Atara Biotherapeutics — SC 13G/A · Feb 9, 2024 Risk: medium
Wasatch Advisors LP, an investment adviser, filed an amended SC 13G/A on February 9, 2024, indicating they no longer hold any shares of Atara Biotherapeutics, I
Goldman Sachs Amends Atara Bio Stake on Dec 29 — SC 13G/A · Feb 6, 2024
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 6, 2024, indicating a change in their beneficial ownership of Atara Biotherapeutics, Inc. common
BlackRock Amends Atara Bio Stake, Signals Portfolio Adjustment — SC 13G/A · Jan 26, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating a change in its ownership of Atara Biotherapeutics, Inc. common stock as of Decem
State Street Corp. Updates Passive Stake in Atara Biotherapeutics — SC 13G/A · Jan 22, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Atara Biotherapeutics Inc. c

Risk Profile

Risk Assessment: Of ATRA's 34 recent filings, 2 were flagged as high-risk, 19 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Atara Biotherapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

Revenue: $119.177M
Net Income: $36.094M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $5.742M
Operating Margin: N/A
Total Assets: $30.167M
Total Debt: N/A

Key Executives

Anh Co Nguyen
Pascal Touchon
Gregory A. Ciongoli
Richard M. Brand
Erica L. Hogan
Dr. Pascal Touchon

Industry Context

Atara Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on allogeneic T-cell immunotherapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory requirements. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies, often requiring substantial funding.

Top Tags

executive-compensation (5) · corporate-governance (5) · Biotechnology (4) · restructuring (4) · disposal (4) · sec-filing (4) · 10-Q (4) · financials (4) · biotech (4) · biotechnology (3)

Key Numbers

Net Income (9M 2025): $36.094M — Significant turnaround from $72.710M net loss in 9M 2024.
Cash & Cash Equivalents (Sep 30, 2025): $5.742M — Down from $25.030M at Dec 31, 2024, indicating severe liquidity issues.
Commercialization Revenue (9M 2025): $119.177M — Increased from $96.187M in 9M 2024, driving YTD profit.
Commercialization Revenue (Q3 2025): $3.453M — Sharp decline from $40.190M in Q3 2024, raising sustainability concerns.
R&D Expenses (9M 2025): $37.668M — Substantial reduction from $122.762M in 9M 2024, reflecting strategic cuts.
Total Current Assets (Sep 30, 2025): $18.432M — Decreased significantly from $64.894M at Dec 31, 2024.
Total Current Liabilities (Sep 30, 2025): $18.057M — Decreased from $134.574M at Dec 31, 2024, but still high relative to current assets.
Shares Outstanding (Nov 6, 2025): 7,210,235 — Increased from 5,859,000 at Dec 31, 2024, indicating dilution.
Total Stockholders' Equity (Deficit) (Sep 30, 2025): ($36.634M) — Improved from ($97.283M) at Dec 31, 2024, but remains negative.
Net Cash Used in Operating Activities (9M 2025): ($45.243M) — Consistent cash burn from ($44.246M) in 9M 2024.
Net Loss: $58.1M — Reduced from $100.2M year-over-year, indicating improved financial efficiency.
Revenue: $2.5M — Increased from $1.8M, primarily from the Pierre Fabre agreement.
R&D Expenses: $38.7M — Decreased from $67.5M, reflecting pipeline prioritization.
G&A Expenses: $21.9M — Decreased from $34.5M, showing operational cost control.
Cash & Equivalents: $105.3M — Down from $160.1M, highlighting significant cash burn.

Forward-Looking Statements

{"claim":"Atara Biotherapeutics' stock price may experience downward pressure due to this institutional divestment.","entity":"Atara Biotherapeutics, Inc.","targetDate":"short-term","confidence":"medium"}
{"claim":"Other institutional investors might re-evaluate their positions in Atara Biotherapeutics following Wasatch Advisors LP's exit.","entity":"Atara Biotherapeutics, Inc.","targetDate":"medium-term","confidence":"low"}

Related Companies

PFRF · PFE · BMY

Frequently Asked Questions

What are the latest SEC filings for Atara Biotherapeutics, INC. (ATRA)?

Atara Biotherapeutics, INC. has 50 recent SEC filings from Jan 2024 to Mar 2026, including 24 8-K, 13 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ATRA filings?

Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Atara Biotherapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Atara Biotherapeutics, INC. (ATRA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Atara Biotherapeutics, INC.?

Key financial highlights from Atara Biotherapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ATRA?

The investment thesis for ATRA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Atara Biotherapeutics, INC.?

Key executives identified across Atara Biotherapeutics, INC.'s filings include Anh Co Nguyen, Pascal Touchon, Gregory A. Ciongoli, Richard M. Brand, Erica L. Hogan and 1 others.

What are the main risk factors for Atara Biotherapeutics, INC. stock?

Of ATRA's 34 assessed filings, 2 were flagged high-risk, 19 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Atara Biotherapeutics, INC.?

Recent forward-looking statements from Atara Biotherapeutics, INC. include guidance on {"claim":"Atara Biotherapeutics' stock price may experience downward pressure due to this institutional divestment.","en and 1 other predictions.